Quantum Cyber N.V. (QUCY) stock
Close on Nov 11, 2026Market cap $52.12MP/E –Yield –
Quantum Cyber N.V. saw revenue fall 39.9% to $537.08K over fiscal 2025. Free cash flow was -$16.00M. At the latest close the market valued the company at $52.12M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $52.12M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.23
- Dividend yield
- –
- Free cash flow yield
- -30.70%
Fundamentals
- Revenue
- $537.08K
- Net income
- -$26.29M
- EPS, diluted
- -$1.66
- Free cash flow
- -$16.00M
- Book value per share
- $0.25
- Diluted shares
- 64M
Trading
- Previous close
- $0.69
- Open
- $0.70
- Day's range
- $0.57 – $0.72
- Volume
- 479,777
- Average volume (20 days)
- 366,457
- Beta (5 years)
- 2.69
- 52-week range
- $0.30 – $4.93
- RSI (14 days)
- 26.0
- Volatility (1 year)
- 357.2%
- Relative volume
- 0.74×
- WACC
- 17.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | QUCY | S&P 500 | Difference | QUCY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -54.1% | -2.4% | −51.7 pts | ||
| 3 months | -54.7% | -1.2% | −53.6 pts | ||
| Year to date | -44.6% | +12.3% | −56.9 pts | ||
| 1 year | -52.3% | +12.4% | −64.8 pts | ||
| 3 years | -72.3% | +78.8% | −151.1 pts | -34.8% | +21.4% |
| 5 years | -93.4% | +75.2% | −168.6 pts | -41.9% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Quantum Cyber filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- News
About Quantum Cyber
Pharmaceutical Preparations
Mainz Biomed N.V., operating as Quantum Cyber, is a molecular diagnostics company focused on developing in-vitro diagnostic solutions for cancer detection while expanding into post-quantum cybersecurity. Its primary research and clinical development efforts target non-invasive screening tools for pancreatic cancer, notably a blood-based test employing licensed mRNA biomarkers with proprietary artificial intelligence algorithms, alongside an early-stage stool-based candidate called PancAlert. The company historically commercialized ColoAlert, an at-home colorectal cancer diagnostic kit, and developed related screening technologies before divesting those assets to prioritize pancreatic cancer diagnostics.
Company profile, executives and historyQuantum Cyber stock: common questions
What is Quantum Cyber's stock price?
QUCY closed at $0.62 on Nov 11, 2026, down 10.14% on the day. Over the past 52 weeks it traded between $0.30 and $4.93.
What is Quantum Cyber's market cap?
Quantum Cyber was worth $52.12M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is QUCY's P/E ratio?
Quantum Cyber lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.66), so it has no meaningful P/E ratio.
How much revenue does Quantum Cyber make?
Quantum Cyber reported revenue of $537.08K for fiscal 2025, down 39.9% from a year earlier.
Does Quantum Cyber pay a dividend?
No. Quantum Cyber has not paid a cash dividend over the last twelve months.
How has QUCY stock performed over the past year?
Including dividends, QUCY returned -52.3% over the past year, against +12.4% for the S&P 500.
Who are Quantum Cyber's competitors?
Companies most similar to Quantum Cyber by business, industry and size include ONCO, XCUR, GDTC, SLN, ALLR.
See a number that looks wrong?